-
Another breakthrough after AlphaFold!
Time of Update: 2021-09-13
RoseTTAFold system on the cover of Science magazine In addition to AlphaFold, another system called RoseTTAFold developed by the research team at the University of Washington has also made important progress in predicting protein structure .
-
Inventory of sales expenses of 15 multinational pharmaceutical companies in the first half of the year: the highest is more than 10 billion, and the proportion is declining year by year.
Time of Update: 2021-09-13
There is no doubt that although AstraZeneca’s overall sales expenditures accounted for the highest proportion of revenue among multinational pharmaceutical companies, data in recent years have clearly pointed out that its proportion has declined rapidly.
-
The fifth round of national procurement, implementation time announced
Time of Update: 2021-09-13
HenanHenan On August 31, the Henan Provincial Medical Security Bureau issued the "Notice on Doing a Good Job in the Implementation of the Fifth Batch of National Organized Drug Centralized Procurement and Chongqing Pharmaceutical Procurement Alliance to ensure supply, stable price and quantity procurement .
-
Japan: Impurity particles in American Modena vaccine are visible to the naked eye. 1.63 million doses are suspended
Time of Update: 2021-09-13
A few days ago, the Shiji News Agency said that a total of about 570,000 doses of Modena vaccine were found to contain impurities.
-
Takeda Vonolasen is about to be approved for new indications, P-CABs intensify competition in the domestic acid suppressant market
Time of Update: 2021-09-13
In February 2015, the drug was approved in Japan for the treatment of acid-related diseases, including reflux esophagitis, gastric ulcer, duodenal ulcer, and prevention during treatment with low-dose aspirin or non-steroidal anti-inflammatory drugs Recurrence of gastric ulcer or duodenal ulcer and eradication of Helicobacter pylori were launched in South Korea in July 2018 .
-
FDA releases draft guidelines for alternative dosing regimens for PD-1 and PD-L1 cancer immunotherapy
Time of Update: 2021-09-13
S. FDA issued on August 25 the draft guidelines of "Pharmackinetic-based Standards Supporting Alternative Dosing Schemes of PD-1 or PD-L1 Blocking Antibodies for the Treatment of Cancer Patients" to help sponsors "seeking and Approval of different alternative intravenous (IV) dosing regimens tested in clinical efficacy and safety trials" .
-
EQRx: "Introduction" accelerator for overseas innovative drugs
Time of Update: 2021-09-13
However, EQRx, a start-up company established in the United States in early 2020, is committed to making lower-priced innovative drugs quickly accessible in the US market, and may become one of the forces that accelerate the "involution" of overseas innovative drugs .
-
Gilead vs. Bristol-Myers Squibb's $1.2 billion CAR-T patent case reversed
Time of Update: 2021-09-13
S. Court of Appeals overturned the previous judgment and ruled that Gilead Yescarta does not need to pay Bristol-Myers Squibb the 1.
2 billion CAR-T patent infringement case, the core products and technologies involved are mainly concentrated in Yescarta, a subsidiary of Gilead, and Juno Therapeutics, a subsidiary of Bristol-Myers Squibb, which targets CD19 CAR-T technology .
-
$1.4 billion antithrombotic drug!
Time of Update: 2021-09-13
com's sales database of multinational listed companies According to data from Meinenet, the global sales of Edoxaban have grown steadily in recent years, reaching 154.
-
The second shot of the collection of consumables is about to fire! Will the average drop of these four types of products exceed 80%? How are the rules of one product one policy formulated? Before the market share was less than 30%, can domestic substitution be achieved smoothly?
Time of Update: 2021-09-13
In order to better promote the centralized procurement of artificial joints, on August 26, the State Organization of the Joint Procurement Office of High-Value Medical Consumables conducted a training meeting for participating companies to interpret and answer questions on the procurement documents .
-
Junshi Biology's mid-term report released: revenue surged by 268% in the first half of the year, over 40 innovative pipelines attracted attention
Time of Update: 2021-09-13
Also in February of this year, the new crown neutralizing antibody esvirizumab jointly developed by Junshi Biotech and domestic scientific research institutions was granted the US FDA Emergency Use Authorization (EUA).
-
Dongyangguang Pharmaceutical, Qilu...59 new drugs were approved for clinical trials, Hengrui’s 11th category 1 new drug was submitted for production, and Amgen’s new drug struck
Time of Update: 2021-09-13
3 billion imported blockbuster new drugs are reported for production; Two Class 1 new drugs of Zhengda Tianqing and Cinda were approved for clinical use; New anti-AD drug, the first domestic Tau antibody to apply for clinical application; Kelun, Hausen, CSPC.
-
Antitrust is really here!
Time of Update: 2021-09-13
Strengthening anti-monopoly and deepening the implementation of fair competition policies are the inherent requirements for improving the socialist market economy system The pharmaceutical industry is a key area of anti-monopoly this year .
-
The first in China! Qilu Pharmaceutical's Disumab Biosimilar Applied for Listing
Time of Update: 2021-09-13
The first and only RANKL inhibitor approved for this indication in China Although Amgen’s original Disulumab injection has a "first-mover" advantage, with Qilu Pharmaceutical's Disulumab biosimilar drug and other latecomers approved, the market space of the former will be squeezed .
-
Depth|Consolidate and absorb the reform achievements, improve the registration and filing system, and welcome new regulations for the management of medical device registration and filing
Time of Update: 2021-09-13
In addition to the commonality with the management of medical device registration and filing, the requirements for the inspection of in vitro diagnostic reagents in different packaging specifications, inspection report requirements, and the use of national standard products Special requirements are put forward in terms of requirements, clinical evaluation and clinical trials .
-
Expanding the immunotherapy pipeline, Baiming Xinkang acquires Aptope assets
Time of Update: 2021-09-13
Apitope's product pipeline focuses on the field of autoimmune diseases, including several innovative drug projects in the clinical, pre-clinical, and research and development stages .
Apitope has developed a series of clinical stage products for antigen-specific immunotherapy, including the treatment of toxic diffuse goiter.
-
CSPC's 2 bio-pharmaceuticals have been clinically approved, and domestically produced hepatitis B class 1 new drugs are coming!
Time of Update: 2021-09-13
Zorifertinib tablets The class 1 new drug zorifertinib tablets declared by Chentai Medicine has obtained the implied license of clinical trials, and it is planned to be developed for the treatment of non-small cell lung cancer (NSCLC) .
-
Behind the cut-off of supply by pharmaceutical companies: Is the low price of centralized procurement really affecting profits?
Time of Update: 2021-09-13
Regarding North China Pharmaceutical’s breach of contract, the United Procurement Office has stated in its announcement on August 20 that the company’s ibuprofen sustained-release capsules selected in the third batch of nationally organized drug procurement failed to supply the agreed procurement volume in Shandong Province according to the agreement.
-
Analysis of 271 drugs competing for the new version of the medical insurance catalogue: The opportunities for listed drugs before 2016 are elusive, and monoclonal antibodies and tinib are still active
Time of Update: 2021-09-13
Outlook: The adjustment of the medical insurance catalog in 2021 is imminent. From the selection direction of the catalog, it can be seen that innovative drugs and new indications will be the main m
-
With the most approved indications and the widest coverage of medical insurance, Hengrui Pharmaceuticals strives to promote PD-1 to benefit patients
Time of Update: 2021-09-13
After being included in the provincial special medicine management scope, even if some hospitals have time to introduce carrelizumab and other national anti-cancer drugs in the future, patients in Jiangsu Province can still buy these life-saving drugs from designated special medicine medical insurance pharmacies and enjoy them.